Skip to main content

Advertisement

Log in

Report on nationwide pooled data and cohort investigation in UFT phase II study

  • Original Articles
  • UFT, Futraful, Uracil, Biochemical Modulation
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

UFT is a compound in which futraful (FT) and uracil are combined at a ratio of 1:4. UFT was given orally at a daily dose of 300–600 mg in a phase II study. Pooled data on a UFT phase II study of 438 evaluable patients, at 104 institutions revealed a response in carcinoma of the stomach (27.7%), pancreas (25.0%), gallbladder and bile duct (25.0%), liver (19.2%), colon and rectum (25.0%), breast (32.0%), and lung (7.0%). The mainly gastrointestinal toxicity resulted in anorexia (24.3%), nausea and vomiting (12.5%), and diarrhea (11.8%). On the other hand, hematological toxicity was rare and mild. To analyze the lifeprolonging effect of the therapy, a cohort study was carried out in 438 cases collected in the UFT phase II study 5 years after the commencement of the therapy. The 50% survival time for 185 patients with gastric cancer was 185 days. The corresponding times in 54 patients with colorectal cancer and 49 with breast cancer were 227 and 505 days, respectively. A historical comparative study of UFT and FT, which was administered in the same institutions for equal evaluation, revealed that UFT had a significantly better effect than FT without more pronounced side effects with the equivalent dose schedule. In conclusion, UFT can be considered a useful agent against cancers over a broad spectrum, especially in gastrointestinal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Fujii S, Ikenaka K, Fukushima M, Shirasaka T (1978) Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Jpn J Cancer Res (Gann) 69: 763

    Google Scholar 

  2. Fujii S, Kitano S, Ikenaka K, Shirasaka T (1979) Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil in rodents. Jpn J Cancer Res (Gann) 70: 209

    Google Scholar 

  3. Fujii S, Kitanos S, Ikenaka K, Shirasaka T (1979) Studies on coadministration of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivatives. Jpn J Cancer Chemother 6: 377

    Google Scholar 

  4. Fujii S, Kitano S, Ikenaka K, Fukushima M, Shirasaka T (1979) Coadministration of thymidine or thymine on antitumor activity of FT-207 or 5-fluorouracil. Jpn J Cancer Chemother 6: 1079

    Google Scholar 

  5. Fukui Y, Imabayashi N, Nishi M, Majima K, Yamamura M, Hioki K, Yamamoto M (1980) Clinical study on the enhancement of drug delivery into tumor tissue by using UFT. Jpn J Cancer Chemother 7: 2124

    Google Scholar 

  6. Furue H, Uchino H, Orita K, Kimura T, Goto Y, Kondo T, Sato S, Takino T, Taguchi T, Nakao I, Nakajima T, Fujimoto S, Miyazaki T, Miyoshi A, Yachi A, Yoshida K, Ogawa N, for SPG Cooperative Study Group of Immunochemotherapy for Gastric Cancer (1985) Clinical evaluation of schizophylan (SPG) in advanced gastric cancer (the second report). A randomized controlled study. Jpn J Cancer Chemother 12: 1272

    Google Scholar 

  7. Ikenaka K, Shirasaka T, Kitano S, Fujii S (1979) Effect of uracil on metabolism of 5-fluorouracil in vitro. Jpn J Cancer Res (Gann) 70: 353

    Google Scholar 

  8. Inoue K, Ogawa M, Inagaki J, Horikoshi N, Ikeda K, Nakada H, Usui N, Asachi K, Tada A, Yamazaki H (1984) A randomized trial and adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer. Jpn J Cancer Chemother 11: 1832

    Google Scholar 

  9. Inuyama Y, Fujii M, Mashino S, Tanaka J, Takaoka T, Kohno N (1983) Clinical effect of UFT therapy for head and neck cancer. Jpn J Cancer Chemother 10: 90

    Google Scholar 

  10. Jato J, Windheuser JJ (1973) 5-Fluorouracil and derivatives in cancer chemotherapy III. J Pharm Sci 62: 1975

    Google Scholar 

  11. Kimura K, Suga S, Shimaji T, Kitamura M, Kubo K, Suzuoki Y, Isobe K (1980) Clinical basis of chemotherapy for gastric cancer with uracil and 1-(2′-tetrahydrofuryl)-5-fluorouracil. Gastroenterol Jpn 15: 324

    Google Scholar 

  12. Kirkwood JM, Ensminger W, Rosowsky A (1980) Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in phase I trial. Cancer Res 40: 107

    Google Scholar 

  13. Kunitomo K, Kuwashima T, Korematsu H, Tamura T, Yoshikawa H, Toyosaki M, Komi N (1982) Clinical trial of UFT against recurrent or advanced carcinomas. Jpn J Cancer Chemother 9: 72

    Google Scholar 

  14. Kurihara M, Nakajima T (1981) Chemotherapy of stomach cancer. Shinko-igaku, Tokyo

    Google Scholar 

  15. Majima H (1980) Phase I and preliminary phase II study of co-administration of uracil and FT-207 (UFT therapy). Jpn J Cancer Chemother 7: 1383

    Google Scholar 

  16. Mukherjee KL, Heidelberger C (1960) Studies on fluroinated pyrimidines. J Biol Chem 235: 433

    Google Scholar 

  17. Murakami M, Ota K et al. for Cooperative Study Group of UFT Therapy in Chubu District (1980) Clinical results of UFT therapy for malignant tumors under cooperative study (phase II study). Jpn J Cancer Chemother 7: 1579

    Google Scholar 

  18. Nakajima O, Ihara K, Isoda T, Matsumoto A, Komoda M, Imamura Y, Koyama Y, Kimura T (1980) Phase I and II studies on a mixture of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil (UFT). Jpn J Cancer Chemother 7: 1558

    Google Scholar 

  19. Nakano Y, et al. for Osaka Cancer Chemotherapy Cooperative Study Group (1980) Clinical Phase II Study of UFT by Cooperative Study Group. Jpn J Cancer Chemother 7: 1569

    Google Scholar 

  20. Nishioka K, Nomura K, Hashimoto S, Matsumoto M, Yunoki K, Tomomatsu H, Shimogawara H, Ichiki T, Furusho H, Takagi S (1981) Clinical effect of UFT on the advanced cancer with special reference to lung cancer. Jpn J Cancer Chemother 8: 294

    Google Scholar 

  21. Rich MA, Bolaffi JL, Knoll JE (1958) Growth inhibition of a human tumor cell strain by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2′-deoxyuridine reversal studies. Cancer Res 18: 730

    Google Scholar 

  22. Scheiner JM, Kostelak E, Duschinsky R (1957) 5-Fluoropyrimidines as growth inhibitors of microorganisms. Proc Am Assoc Cancer Res 16: 242

    Google Scholar 

  23. Schumacher HJ, Wilson JG, Jordan RJ (1969) Potentiation of the teratogenic effects of 5-fluorouracil by natural pyrimidines. Teratology 2: 99

    Google Scholar 

  24. Shirakawa S, Uehara N, Kita K, Nasu K (1981) Clinical trial on the effect of UFT. Jpn J Cancer Chemother 8: 101

    Google Scholar 

  25. Taguchi T (1984) UFT. Jpn J Cancer Chemother 11: 1692

    Google Scholar 

  26. Taguchi T, Nakano Y, Jikuya K, Fujii S, Ikenaka K, Fukushima M, Shirasaka T (1978) Effect of uracil on the antitumor activity of futraful. Jpn J Cancer Chemother 5: 1161

    Google Scholar 

  27. Taguchi T, Nakano Y, Fujii S, Shirasaka T (1978) determination of 5-fluorouracil levels in tumors, blood, and other tissues. Jpn J Cancer Chemother 5: 1167

    Google Scholar 

  28. Taguchi T, Furue H, Koyama Y, Saito T, Ito I, Majima H, Kimura K, Ota K, Hoshino A, Yamamoto M, Hattori T, Kusumoto G Inokuchi K (1980) Phase I study of UFT (uracil plus futraful preparation). Jpn J Cancer Chemother 7: 966

    Google Scholar 

  29. Taguchi T, Furue H, Kimura T, Kondo T, Hattori T, Itoh I, Ogawa N (1985) End-point results of phase III study of lentinan. Jpn J Cancer Chemother 12: 366

    Google Scholar 

  30. Takino T, Misawa S (1980) Clinical studies on the chemotherapy of advanced cancer with UFT (uracil plus futraful preparation). Jpn J Cancer Chemother 7: 1804

    Google Scholar 

  31. Tamura Y, Okino M, Hongo H, Nakayasu K, Nishikata F, Tokunaga M, Hosoba S, Itoh T, Niimoto M, Hattori T (1981) Phase II study of UFT by collaborative study. Jpn J Cancer Chemother 8: 302

    Google Scholar 

  32. Terasawa T, Koyama H (1986) Breast cancer. Antibiot Chemother 2: 515

    Google Scholar 

  33. Tominaga T, Kaneko H, Ito I (1980) Clinical trial of UFT against advanced cancer. Jpn J Cancer Chemother 7: 2119

    Google Scholar 

  34. Tosen T, Ando K, Ochiai M, Kasajima M, Mori S, Kubochi K (1981) Clinical trial on the effect of UFT. Jpn J Cancer Chemother 8: 715

    Google Scholar 

  35. Watanabe H, Yamamoto S, Naito T, for Tokyo Cancer Chemotherapy Cooperative Study Group (1980) Clinical results of oral UFT therapy under cooperative study. Jpn J Cancer Chemother 7: 1588

    Google Scholar 

  36. Yakeishi Y, Yoshida H, Yokota H, Inui K, Sugama S (1981) Clinical trial of UFT (uracil-futraful preparation) against malignant tumors. Jpn J Cancer Chemother 8: 414

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ota, K., Taguchi, T. & Kimura, K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother. Pharmacol. 22, 333–338 (1988). https://doi.org/10.1007/BF00254241

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00254241

Keywords

Navigation